title: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
abstract: BACKGROUND
  A 79-year-old man presented to his primary care physician with a 2-month history of pruritus ani and a pigmented nodular lesion was discovered in the posterior rectum. The patient had no other symptoms, or any family history of malignancy.
  
  
  METHODS
  Physical examination; excisional biopsy; CT scan of the chest, abdomen and pelvis; lung biopsy; blood tests; tumor immunohistochemistry for KIT, vascular endothelial growth factor platelet-derived growth factor receptor alpha and beta, and mismatch-repair proteins MLH1, MSH2, and MSH6; and KIT and BRAF tumor genotyping.
  
  
  METHODS
  Stage IV M1b metastatic anal mucosal melanoma.
  
  
  RESULTS
  Wide local excision with mucosal advancement of the rectal wall, external-beam radiation, and sorafenib-temozolomide therapy.
authors.affiliation: Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Quintás-Cardama
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Lazar
authors.forename: Scott E
authors.initials: SE
authors.lastname: Woodman
authors.forename: Kevin
authors.initials: K
authors.lastname: Kim
authors.forename: Merrick
authors.initials: M
authors.lastname: Ross
authors.forename: Patrick
authors.initials: P
authors.lastname: Hwu
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000188:drug therapy / Q000628:therapy*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy*; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D003606:Dacarbazine; D000077157:Sorafenib; D019009:Proto-Oncogene Proteins c-kit; D000077204:Temozolomide